StoxFortis Healthcare vs Ipca Laboratories: share price & financials comparison
NSE: FORTIS vs IPCALAB · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Fortis Healthcare vs Ipca Laboratories at a glance
Fortis Healthcare (FORTIS) has a market capitalisation of ₹57,679 Cr, against ₹47,797 Cr for Ipca Laboratories (IPCALAB). Over the past year Ipca Laboratories has returned +45.5%, compared with -25.0% for Fortis Healthcare. On valuation, Ipca Laboratories trades at a lower P/E of 34.1 versus 55.5. Ipca Laboratories earns a higher return on equity (16.2% vs 9.9%). Fortis Healthcare comes out ahead on valuation and growth. Ipca Laboratories comes out ahead on size, profitability, financial health and technicals. Across the scored metrics below, Fortis Healthcare leads on 7 and Ipca Laboratories on 11. On StoxGud's 10-point checklist, Fortis Healthcare scores 4/10 and Ipca Laboratories scores 8/10.
| Metric | Fortis Healthcare | Ipca Laboratories |
|---|---|---|
| Size | ||
| Market cap | ₹57,679 Cr | ₹47,797 Cr |
| Revenue (latest FY) | ₹9,128 Cr | ₹9,646 Cr |
| Net profit (latest FY) | ₹1,042 Cr | ₹1,141 Cr |
| Valuation | ||
| P/E | 55.5 | 34.1 |
| P/B | 5.50 | 5.51 |
| Dividend yield | 0.13% | 0.11% |
| Profitability | ||
| Return on equity | 9.9% | 16.2% |
| Net profit margin | 10.5% | 13.4% |
| Operating margin | 22.2% | 22.5% |
| Growth | ||
| Revenue growth (YoY) | +17.3% | +13.8% |
| Net profit growth (YoY) | -3.0% | +32.8% |
| Revenue CAGR (multi-year) | +17.8% | +12.2% |
| Financial health | ||
| Debt to equity | 0.30 | 0.07 |
| Momentum | ||
| 1-month return | +1.0% | -1.8% |
| 1-year return | -25.0% | +45.5% |
| 3-year CAGR | +27.5% | +21.3% |
| 5-year CAGR | +22.6% | +11.4% |
| 10-year CAGR | +16.8% | +21.4% |
| Distance from 52W high | -25.1% | -6.2% |
| Technicals | ||
| RSI (14) | 62 | 38 |
| Price vs 200-day avg | -14.2% | +11.2% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Fortis Healthcare | Ipca Laboratories |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✗ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✗ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 4/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Fortis Healthcare or Ipca Laboratories?
Fortis Healthcare has a market cap of ₹57,679 Cr and Ipca Laboratories has a market cap of ₹47,797 Cr as of 13 Nov 2026.
Which has a lower P/E, Fortis Healthcare or Ipca Laboratories?
Ipca Laboratories has the lower P/E: Fortis Healthcare trades at 55.5 and Ipca Laboratories at 34.1.
Which gave better returns in the last year, Fortis Healthcare or Ipca Laboratories?
Ipca Laboratories did better: Fortis Healthcare returned -25.0% and Ipca Laboratories returned +45.5% over one year.
What is the difference between Fortis Healthcare and Ipca Laboratories?
Both are NSE-listed companies in Healthcare. Fortis Healthcare is about 1.2 times the size of Ipca Laboratories by market cap. In the latest financial year Fortis Healthcare reported revenue of ₹9,128 Cr and Ipca Laboratories ₹9,646 Cr. Operating margin is 22.2% for Fortis Healthcare and 22.5% for Ipca Laboratories. Debt to equity is 0.30 for Fortis Healthcare and 0.07 for Ipca Laboratories.
Which is better, Fortis Healthcare or Ipca Laboratories?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Fortis Healthcare leads on 7 and Ipca Laboratories on 11. Fortis Healthcare is ahead on valuation and growth. Ipca Laboratories is ahead on size, profitability, financial health and technicals. On StoxGud's rules-based checklist Fortis Healthcare scores 4/10 and Ipca Laboratories scores 8/10. This is information, not advice: consult a SEBI-registered adviser before investing.